Table 7.6a
Immunosuppression Use for Induction, 1996 to 2005
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Transplants	113	130	156	220	304	305	375	344	420	344
With Immunosuppression Info	109	129	152	217	298	303	372	336	408	333
Induction Drugs										
ALG	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	45.9%	48.1%	19.7%	8.3%	1.7%	0.3%	2.4%	0.6%	1.5%	3.3%
OKT3	29.4%	24.8%	15.8%	8.8%	3.0%	0.7%	1.3%	0.9%	0.2%	0.0%
Thymoglobulin	0.0%	0.0%	0.7%	30.0%	37.2%	50.5%	51.9%	50.9%	57.4%	54.4%
Zenapax	0.0%	0.0%	26.3%	36.9%	32.6%	33.3%	25.3%	9.5%	6.6%	6.9%
Simulect	0.0%	0.8%	9.9%	10.6%	17.1%	13.2%	8.3%	8.0%	5.4%	2.7%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	13.4%	19.1%	17.7%
No Induction Drugs Recorded	28.4%	26.4%	36.2%	33.6%	33.2%	25.1%	27.2%	25.9%	20.1%	21.9%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.